Cardiometabolic consequences and pathway of weight gain associated with dolutegravir-based antiretroviral therapy in haiti. A collaborative study between gheskio and ccasanet
Ended Project Grant Awarded Last action
- Award ID
- R21TW012644
- Recipient
-
Les Centres Gheskio UEI ZKDAZLMSN6S8
- Awarding agency
-
Fogarty International Center
National Institutes of Health, Department of Health and Human Services
- Obligated
- $312,665
Award facts
- Assistance listing
- 93.989 International Research and Research Training
- Completion date
- Place of performance
- Haiti
Award details come from USAspending.gov.
Description
- Abstract
- Haiti has the largest number of persons with HIV (PWH) in the caribbean. PWH have a higher risk of developing metabolic and cardiovascular disease (CVD), which are leading causes of mortality among haitians and other residents of low and middle-income countries (LMICS), driven in part by high rates of hypertension, elevated fasting plasma glucose and high body mass index. Weight gain is common early after starting antiretroviral therapy (art), particularly among PWH on an integrase strand transfer inhibitor (INSTI)-based regimen. The INSTI-containing combination regimen of tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) is the most commonly prescribed art regimen in LMICS, but at present there are few data on the consequences of weight gain on art in these settings. Consequently, there is a critical need for innovative approaches to 1) determine the features and severity of cardiometabolic disease risk accompanying weight gain among TLD recipients in LMICS, including insulin sensitivity, blood pressure, lipid profiles and systemic inflammation; and 2) determine the metabolic mechanisms underlying weight gain to guide the development and implementation of effective prevention and treatment strategies. Gheskio (groupe haitien D'etude DU sarcome ET DES infections opportunities) is the largest HIV clinic in the americas, a founding member of ccasanet (the caribbean, central and south america network for HIV epidemiology) and has a 37-year track record of NIH research on HIV and associated comorbidities. Building upon this infrastructure, our multi-disciplinary study will leverage advanced metabolic phenotyping and multiomic data analysis to elucidate the bioenergetic pathways underlying weight gain on TLD and the cardiometabolic consequences among PWH in lmic, where diet and lifestyle factors differ from higher income countries. Aim 1 will assess whether weight gain on TLD is associated with increased insulin resistance, blood pressure, dyslipidemia, and inflammation. We will enroll 200 previously art-naïve patients who initiated TLD at gheskio 12 to 24 months previously and gained
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1 | |
| Amendment | $1 | |
| Amendment | $1 | |
| Amendment | $156,331 | |
| Original award | $156,331 |
Quick answers
Who received award R21TW012644?
R21TW012644 was awarded to Les Centres Gheskio by Fogarty International Center (National Institutes of Health) on July 10, 2023.
How much is award R21TW012644 worth?
$312,665 has been obligated on R21TW012644.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award